- Home
- DBI vs DSGN Comparison
DBI vs DSGN Comparison
Compare DBI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- DSGN
- Stock Information
- Founded
- DBI 1991
- DSGN 2017
- Country
- DBI United States
- DSGN United States
- Employees
- DBI N/A
- DSGN N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- DSGN Health Care
- Exchange
- DBI Nasdaq
- DSGN Nasdaq
- Market Cap
- DBI 292.2M
- DSGN 348.2M
- IPO Year
- DBI 1991
- DSGN 2021
- Fundamental
- Price
- DBI $5.74
- DSGN $4.87
- Analyst Decision
- DBI Hold
- DSGN Hold
- Analyst Count
- DBI 2
- DSGN 3
- Target Price
- DBI $5.75
- DSGN $7.00
- AVG Volume (30 Days)
- DBI 1.4M
- DSGN 220.6K
- Earning Date
- DBI 12-10-2024
- DSGN 03-18-2025
- Dividend Yield
- DBI 3.53%
- DSGN N/A
- EPS Growth
- DBI N/A
- DSGN N/A
- EPS
- DBI N/A
- DSGN N/A
- Revenue
- DBI $3,050,038,000.00
- DSGN N/A
- Revenue This Year
- DBI N/A
- DSGN N/A
- Revenue Next Year
- DBI $2.23
- DSGN N/A
- P/E Ratio
- DBI N/A
- DSGN N/A
- Revenue Growth
- DBI N/A
- DSGN N/A
- 52 Week Low
- DBI $4.36
- DSGN $2.25
- 52 Week High
- DBI $11.57
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- DBI 53.41
- DSGN 42.19
- Support Level
- DBI $5.08
- DSGN $3.71
- Resistance Level
- DBI $5.98
- DSGN $6.81
- Average True Range (ATR)
- DBI 0.38
- DSGN 0.50
- MACD
- DBI 0.04
- DSGN -0.10
- Stochastic Oscillator
- DBI 61.68
- DSGN 37.42
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.